中国癌症杂志 ›› 2014, Vol. 24 ›› Issue (2): 106-111.doi: 10.3969/j.issn.1007-3969.2014.02.005

• 论著 • 上一篇    下一篇

PI3K/Akt/NF-κB通路调控ABCB1/P-gp介导的人结肠癌细胞多药耐药的研究

隋华1,付晓伶1,潘树芳2,石晓兰2,靳宝辉1,朱惠蓉1,任建琳3,李琦1   

  1. 1.上海中医药大学附属曙光医院肿瘤科,上海201203;
    2.上海中医药大学附属普陀医院肿瘤科,上海200062;
    3.上海市中医医院肿瘤科,上海200071
  • 出版日期:2014-02-28 发布日期:2014-03-07
  • 通信作者: 李琦 E-mail:lzwf@hotmail.com
  • 基金资助:
    国家自然科学基金(No:81373862、81202812);
    上海市科委资助项目(No:13140902500);
    上海市教委资助项目(No:2011JW57、12ZZ118);
    上海市卫生局科研项目(No:20114Y013、2010019);
    上海市中医药事业发展三年行动计划(No:ZYSNXD-CC-YJXYYJS20)

PI3K/Akt/NF-κB regulate ABCB1/P-glycoprotein-mediated multidrug resistance in colon carcinoma cells

SUI Hua1,FU Xiao-ling1,PAN Shu-fang2,SHI Xiao-lan2,JIN Bao-hui1,ZHU Hui-rong1,REN Jian-lin3,LI Qi1   

  1. 1.Department of Medical Oncology, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China;
    2.Department of Medical Oncology, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200062, China; 
    3.Department of Oncology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai 200071, China
  • Published:2014-02-28 Online:2014-03-07
  • Contact: LI Qi E-mail: lzwf@hotmail.com

摘要:

背景与目的:肿瘤的多药耐药(multidrug resistanceMDR)基因的表达是目前化疗失败的主要原因,磷脂酰肌醇-3-激酶(phosphoinositide 3-kinasesPI3K)信号通路参与肿瘤多药耐药的发生,但PI3K信号通路与多药耐药的机制尚不明确。本研究旨在探讨PI3K/Akt信号通路及其下游靶点对ATP结合蛋白亚家族1抗体(ATP-binding cassette sub-family B member 1ABCB1)基因编码的P-糖蛋白(P-glycoproteinP-gp)介导的人结肠癌耐奥沙利铂细胞株HCT-116/L-OHP细胞多药耐药性的调控作用。方法:PI3K特异性抑制剂LY294002(20 μmol/L)处理人结肠癌HCT-116/L-OHP细胞2 h后,用细胞计数试剂盒-8(cell counting kit-8CCK-8)检测细胞对奥沙利铂的敏感性;蛋白质印迹法(Western blot)检测相关耐药蛋白P-gp、肺耐药蛋白(lung resistance-related proteinLRP)、多药耐药相关蛋白-2(multidrug resistance-related-2MRP-2)以及PI3K/Akt信号通路下游蛋白Aktp-AktIκBp-IκB的表达变化;CHIPPCR法检测核转录因子κB(NF-κB)ABCB1基因启动子的影响。结果:阻断PI3K/Akt信号通路激活后,奥沙利铂对HCT-116/L-OHP细胞的半数抑制浓度(IC50)(157.48±16.73)μg/mL降至(53.68±3.18)μg/mL,逆转指数为2.93(P<0.01)HCT-116/L-OHP细胞的p-Aktp-IκBP-gp的表达水平明显下降(P<0.01)AktIκBLRPMRP-2表达变化不明显。NF-κB能够与ABCB1基因启动子区域结合。结论:阻断PI3K/AKT信号通路可增强人结肠癌HCT-116/L-OHP耐药细胞的药物敏感性,抑制p-Aktp-IκB的磷酸化表达水平,逆转P-gp介导的肠癌多药耐药。

关键词: 结肠癌, 多药耐药, P-糖蛋白, 磷脂酰肌醇-3-激酶, 核转录因子&kappa, B

Abstract:

Background and purpose: Multidrug resistance (MDR) is the dominating obstacle to the chemotherapy. There is strong evidence that the phosphoinositide 3-kinases (PI3Ks) signaling pathway is involved in MDR phenotype, however, the mechanism of MDR occurrence is still unknown. This study tended to investigate the regulating effect of PI3K/Akt signaling pathway and its downstream target genes in P-glycoprotein (P-gp) (ABCB1 gene encoding)-mediated MDR in human colon carcinoma HCT-116/L-OHP cells. Methods: Pretreatment with PI3K selective inhibitor LY294002 (20 μmol/L) for 2 h, the sensitivity of L-OHP was evaluated by the CCK-8 (cell counting kit-8) assay in HCT-116/L-OHP cells, and the expressions of P-gp, LRP, MRP-2, Akt, p-Akt, IκB and p-IκB were evaluated by Western blot. The activity of ABCB1 promoter was evaluated by chromatin immunoprecipitation analysis (CHIP). Results: After inhibiting the activity of PI3K/Akt signaling pathway, the IC50 value of L-OHP decreased from(157.48±16.73) μg/mL to (53.68±3.18) μg/mL in HCT-116/L-OHP cells, and the reversal index was 2.93 (P<0.01). The expressions of P-gp, p-Akt and p-IκB were down-regulation compared with the concrol group (P<0.01), but the expressions of LRP, MRP-2, Akt and IκB didn't change significantly. CHIP result has confirmed that NF-κB protein could bind to the region of ABCB1 gene promoter in HCT116/L-OHP cells. Conclusion: Blocking of PI3K/Akt/NF-kB signal pathway could increase the drug sensitivity to MDR cells, inhibit the phosphorylation of p-Akt and p-IκB, and reversing ABCB1/P-glycoprotein–mediated multidrug resistance in colon carcinoma cells.

Key words: Colon carcinoma, Multidrug-resistance, P-glycoprotein, Phosphoinositide 3-kinases (PI3K), Nuclear factor kappa-light-chain-enhancer of activated B (NF-κB)